Lifeway Foods Inc. (Nasdaq:LWAY) announced results for three and six months ended June 30, 2011. Second quarter of 2011 gross sales increased 28% to $19.9 million compared to $15.5 million for the second quarter of 2010. This increase is primarily attributable to increased sales and growing awareness of benefits of Lifeway’s flagship line, Kefir, as well as ProBugs� Organic Kefir for kids, and the successful introduction of new product lines such as Bio Kefir�. In addition, Lifeway Frozen Kefir contributed approximately $0.2 million in sales during the second quarter of 2011. The frozen kefir line was launched in April 2011.
Lifeway Foods, Inc., together with its subsidiaries, manufactures dairy and non-dairy health food products.
China Medical Technologies Inc. (Nasdaq:CMED) announced its unaudited financial results for the first fiscal quarter ended June 30, 2011 (”1Q FY2011″). The Company reported net revenues of RMB237.1 million (US$36.7 million) for 1Q FY2011, representing a 27.4% increase from the corresponding period of FY2010. The Company’s revenues are currently generated from two segments, molecular diagnostic systems and immunodiagnostic systems. The molecular diagnostic system segment mainly includes FISH products and SPR products while the immunodiagnostic system segment consists of ECLIA products.
China Medical Technologies, Inc., a medical device company, develops, manufactures, and markets immunodiagnostic and molecular diagnostic products.
Perrigo Co. (Nasdaq:PRGO) announced results for its fourth quarter and full year ended June 25, 2011.Net sales from continuing operations for the fourth quarter of fiscal 2011 were approximately $705 million, an increase of 14% compared to last year. Reported income from continuing operations was approximately $86 million, or $0.91 per share, a strong increase over $49 million, or $0.53 per share, a year ago.
Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, infant formulas, active pharmaceutical ingredients (API), and pharmaceutical and medical diagnostic products worldwide.
Cleantech Transit, Inc. (CLNO)
Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (www.phoenixenergy.net). This project could benefit the Company’s manufacturing clients worldwide.
Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company’s ability to earn in 25% of the 500KW Merced Project.
The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.
Biomass is biological material derived from living, or recently living organisms. In the context of biomass for energy this is often used to mean plant based material, but biomass can equally apply to both animal and vegetable derived material.
The carbon used to construct biomass is absorbed from the atmosphere as carbon dioxide (CO2) by plant life, using energy from the sun.
Plants may subsequently be eaten by animals and thus converted into animal biomass. However the primary absorption is performed by plants.
For more information about Cleantech Transit, Inc. visit its website www.cleantechtransitinc.com
No comments :
Post a Comment